PARP

poly ADP ribose polymerase



PARP is a family of proteins involved in a number of cellular processes involving mainly DNA repair and programmed cell death. The PARP family comprises 17 members. They have all very different structures and functions in the cell. PARP1, PARP2, VPARP (PARP4), Tankyrase-1 and -2 (PARP-5a or TNKS, and PARP-5b or TNKS2) have a confirmed PARP activity. Others include PARP3, PARP6, TIPARP (or PARP7), PARP8, PARP9, PARP10, PARP11, PARP12, PARP14, PARP15, and PARP16. PARP is found in the cell's nucleus. The main role is to detect and signal single-strand DNA breaks (SSB) to the enzymatic machinery involved in the SSB repair.

PARP Inhibitors & Modulators

3-Aminobenzamide

(PARP-IN-1)

Cat. No.: HY-12022

Bioactivity: 3-Aminobenzamide is a potent inhibitor of **PARP** with **IC_{50}** of appr 50 nM in CHO cells, and acts as a mediator of oxidant-induced myocyte dysfunction during reperfusion.

Purity: 99.92%
Clinical Data: Phase 2
Size: 10mM x 1mL in Water, 200 mg, 500 mg



A-966492

Cat. No.: HY-10614

Bioactivity: A-966492 is a novel and potent inhibitor of **PARP1** and **PARP2** with **K_i** of 1 nM and 1.5 nM, respectively.

Purity: 98.59%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



AG14361

Cat. No.: HY-12032

Bioactivity: AG14361 is a potent **PARP-1** inhibitor, with a **K_i** of < 5 nM, and in permeabilized SW620 and intact SW620 cells, the **IC_{50}**s are 29 nM and 14 nM, respectively.

Purity: 99.41%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



AZ6102

Cat. No.: HY-12975

Bioactivity: AZ6102 is a potent dual **TNKS1** and **TNKS2** inhibitor, with **IC_{50}**s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with **IC_{50}**s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PAR...

Purity: 99.65%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



AZD-2461

Cat. No.: HY-13536

Bioactivity: AZD-2461 is a potent **PARP** inhibitor, with **IC_{50}**s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.

Purity: 98.39%
Clinical Data: Phase 1
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



BGP-15

Cat. No.: HY-100828

Bioactivity: BGP-15 is a **PARP** inhibitor, with an **IC_{50}** and a **K_i** of 120 and 57 μM, respectively.

Purity: 98.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg



BRCA1-IN-1

Cat. No.: HY-100863

Bioactivity: BRCA1-IN-1 is a novel small-molecule-like **BRCA1** inhibitor with **IC_{50}** and **K_i** of 0.53 μM and 0.71 μM, respecrively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



Dehydrocorydaline

(13-Methylpalmatine)

Cat. No.: HY-N0674

Bioactivity: Dehydrocorydaline (13-Methylpalmatine) is an alkaloid isolated from traditional Chinese herb Corydalis yanhusuo W.T. Wang. Dehydrocorydaline regulates protein expression of **Bax**, **Bcl-2**; activates **caspase-7**, **caspase-8**, and inactivates **PARP**.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg



E7449

Cat. No.: HY-12418

Bioactivity: E7449 is a potent **PARP1** and **PARP2** inhibitor and also inhibits **TNKS1** and **TNKS2**, with **IC_{50}**s of 2.0, 1.0, 50 and 50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using ^{32}P-NAD $^{+}$ as substrate.

Purity: 99.0%
Clinical Data: Phase 2
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



G007-LK

Cat. No.: HY-12438

Bioactivity: G007-LK is a potent and selective inhibitor of **TNKS1** and **TNKS2**, with **IC_{50}**s of 46 nM and 25 nM, respectively.

Purity: 99.24%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com

GeA-69

Cat. No.: HY-108708

Bioactivity: GeA-69 is a selective, highly cell permeable allosteric inhibitor of **poly-adenosine-diphosphate-ribose polymerase 14 (PARP14)** targeting macrodomain 2, with a K_d of 2.1 μM [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg



Iniparib

(BSI-201; NSC-746045; IND-71677)

Cat. No.: HY-12015

Bioactivity: Iniparib (BSI-201) is an irreversible inhibitor of **PARP1**, used in the research of triple negative breast cancer.

Purity: 99.65%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg, 200 mg, 500 mg



JW 55

Cat. No.: HY-13968

Bioactivity: JW 55 is a potent and selective **β-catenin** signaling pathway inhibitor, which functions via inhibition of the PARP domain of tankyrase 1 and tankyrase 2 (TNKS1/2). JW 55 decreases auto-PARsylation of TNKS1/2 in vitro with IC_{50}s of 1.9 μM and 830 nM respectively.

Purity: 99.10%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg, 100 mg



K-756

Cat. No.: HY-U00422

Bioactivity: K-756 is a direct and selective **tankyrase** (**TNKS**) inhibitor, which inhibits the ADP-ribosylation activity of **TNKS1** and **TNKS2** with IC_{50}s of 31 and 36 nM, respectively.

Purity: 99.0%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg



ME0328

Cat. No.: HY-100225

Bioactivity: ME0328 is a potent and selective **ARTD3**/ **PARP3** inhibitor with an IC_{50} of 0.89±0.28 μM.

Purity: 99.34%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



MN-64

Cat. No.: HY-19351

Bioactivity: MN-64 is a potent **tankyrase 1** inhibitor, with IC_{50}s of 6 nM, 72 nM, 19.1 μM, and 39.4 μM for **TNKS1**, TNKS2, ARTD1 and ARTD2, respectively.

Purity: 98.22%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Niraparib

(MK-4827)

Cat. No.: HY-10619

Bioactivity: Niraparib (MK-4827) is a highly potent **PARP1** and **PARP2** inhibitor with IC_{50}s of 3.8 and 2.1 nM, respectively.

Purity: 99.93%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Niraparib hydrochloride

(MK-4827 (hydrochloride))

Cat. No.: HY-10619A

Bioactivity: Niraparib hydrochloride (MK-4827 hydrochloride) is an excellent **PARP1** and **PARP2** inhibitor with IC_{50} of 3.8 and 2.1 nM, respectively.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



Niraparib R-enantiomer

(MK 4827 (R-enantiomer))

Cat. No.: HY-10619D

Bioactivity: Niraparib R-enantiomer (MK-4827 R-enantiomer) is an excellent **PARP1** inhibitor with IC_{50} of 2.4 nM.

Purity: 98.58%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



Niraparib tosylate

(MK-4827 (tosylate))

Cat. No.: HY-10619B

Bioactivity: Niraparib tosylate (MK-4827 tosylate) is an excellent **PARP1** and **PARP2** inhibitor with an IC_{50} of 3.8 and 2.1 nM, respectively.

Purity: 99.52%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



NMS-P118

Cat. No.: HY-18954

Bioactivity: NMS-P118 is a potent, orally available, and highly selective **PARP-1** Inhibitor for cancer therapy.

Purity: 99.08%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



NMS-P515

Cat. No.: HY-128599

Bioactivity: NMS-P515 is a potent and stereospecific **PARP-1** inhibitor, with an **IC_{50}** of 27 nM in hela cells. Anti-tumor activity [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg, 100 mg



NVP-TNKS656

(TNKS656)

Cat. No.: HY-13990

Bioactivity: NVP-TNKS656 is a highly potent, selective, and orally active **TNKS2** inhibitor with **IC_{50}** of 6 nM, and is > 300 fold selectivity against **PARP1** and **PARP2**.

Purity: 99.31%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Olaparib

(AZD2281; KU0059436)

Cat. No.: HY-10162

Bioactivity: Olaparib (AZD2281;KU0059436) is a potent and oral **PARP** inhibitor with **IC_{50}**s of 5 and 1 nM for **PARP1** and **PARP2**, respectively.

Purity: 99.98%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg, 200 mg, 500 mg, 1 g, 2 g



Pamiparib

(BGB-290)

Cat. No.: HY-104044

Bioactivity: Pamiparib is a **PARP** inhibitor which can be used for the treatment of various cancers including the solid tumor, extracted from patent WO 2013097225 A1.

Purity: 99.97%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



PARP-2-IN-1

Cat. No.: HY-102035

Bioactivity: PARP-2-IN-1 is a potent and selective **PARP-2** inhibitor with an **IC_{50}** of 11.5 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



PJ34

Cat. No.: HY-13688A

Bioactivity: PJ34 is a potent specific inhibitor of **PARPI/ 2** with **IC_{50}** of 110 nM and 86 nM, respectively.

Purity: 98.0%
Clinical Data: No Development Reported
Size: 10 mg, 50 mg, 100 mg



PJ34 hydrochloride

Cat. No.: HY-13688

Bioactivity: PJ34 hydrochloride is an inhibitor of **PARPI1/2** with **IC_{50}** of 110 nM and 86 nM, respectively.

Purity: 97.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in Water,
10 mg, 50 mg, 100 mg



PROTAC PARP1 degrader

Cat. No.: HY-114324

Bioactivity: PROTAC PARP1 degrader is a **PARP1** degrader based on the **PROTAC** technology. It induces significant PARP1 cleavage and programmed cell death. PROTAC PARP1 degrader at 10 μM at 24 h inhibits MDA-MB-231 cell line with an **IC_{50}** of 6.12 μM.

Purity: >98%
Clinical Data: No Development Reported
Size: 100 mg, 250 mg



RK-287107

Cat. No.: HY-123892

Bioactivity: RK-287107 is a potent and specific **tankyrase** inhibitor with **IC_{50}**s of 14.3 and 10.6 nM for **tankyrase-1** and **tankyrase-2**, respectively. RK-287107 blocks colorectal cancer cell growth [1].

Purity: >98%
Clinical Data: No Development Reported
Size: 500 mg, 250 mg



Rucaparib

(AG014699; PF-01367338) Cat. No.: HY-10617A

Bioactivity: Rucaparib (AG014699) is an inhibitor of **PARP** with K_i of 1.4 nM for PARP1 in a cell-free assay, and also shows binding affinity to eight other PARP domains.

Purity: >98%
Clinical Data: Launched
Size: 5 mg, 10 mg, 50 mg, 100 mg



Rucaparib Camsylate

Cat. No.: HY-102003

Bioactivity: Rucaparib Camsylate is an inhibitor of **PARP** with a K_i of 1.4 nM for PARP1, and also shows binding affinity to eight other PARP domains.

Purity: 99.81%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



Rucaparib phosphate

(AG-014699 phosphate; PF-01367338 phosphate) Cat. No.: HY-10617

Bioactivity: Rucaparib phosphate (AG-014699 phosphate) is a potent and oral **PARP** inhibitor, with a K_i of 1.4 nM for PARP1 in cell-free assay, also showing binding affinity to eight other PARP domains.

Purity: 99.89%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Talazoparib

(BMN-673; LT-673) Cat. No.: HY-16106

Bioactivity: Talazoparib (BMN-673) is a highly potent **PARP1/2** inhibitor with K_is of 1.2 nM and 0.87 nM, respectively.

Purity: 99.83%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Talazoparib 8R,9S

(BMN-673 (8R,9S); (8R,9S)-LT-673) Cat. No.: HY-16106A

Bioactivity: Talazoparib 8R,9S (BMN-673 8R,9S) is an enantiomer of Talazoparib, less active than Talazoparib on the inhibition of **PARP1**, with an IC_{50} of 144 nM.

Purity: 95.08%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Talazoparib tosylate

(BMN 673ts) Cat. No.: HY-108413

Bioactivity: Talazoparib tosylate (BMN 673ts) is a novel, potent and orally available **PARP1/2** inhibitor with an IC_{50} of 0.57 nM for PARP1.

Purity: 99.74%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



UPF 1069

Cat. No.: HY-14478

Bioactivity: UPF 1069 is a **PARP** inhibitor, with IC_{50}s of 8 and 0.3 μM for PARP-1 and PARP-2, respectively.

Purity: 98.88%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



Veliparib

(ABT-888) Cat. No.: HY-10129

Bioactivity: Veliparib is a potent **PARP** inhibitor, inhibiting **PARP1** and **PARP2** with K_is of 5.2 and 2.9 nM, respectively.

Purity: 98.0%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Veliparib dihydrochloride

(ABT-888 dihydrochloride) Cat. No.: HY-10130

Bioactivity: Veliparib (dihydrochloride) is a potent inhibitor of **PARP1** and **PARP2** with K_is of 5.2 nM and 2.9 nM in cell-free assays, respectively.

Purity: 99.62%
Clinical Data: Phase 3
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg, 200 mg



WD2000-012547

Cat. No.: HY-U00223

Bioactivity: WD2000-012547 is a selective poly(ADP-ribose)-polymerase (PARP-1) inhibitor with a pK_i of 8.221.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg, 20 mg



XAV-939

Cat. No.: HY-15147

Bioactivity: XAV-939 is a **tankyrase (TNKS)** inhibitor and an indirect inhibitor of **Wnt/β-catenin signaling**, with **IC_{50}**s of 5 and 2 nM for TNKS1 and TNKS2, respectively.

Purity: 98.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg, 200 mg



Tel: 609-228-6898 Fax: 609-228-5909 Email: sales@MedChemExpress.com